摘要
Dear Editor,We read with great interest the article by Wang et al which investigated the predictive factors for short-term outcomes related to central subfield foveal thickness (CSFT) after intravitreal bevacizumab (IVB; Avastin, Genentech Inc., South Francisco, CA, USA) injections in 60 patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). The authors concluded that IVB significantly improved visual acuity and CSFT after 3mo.
Dear Editor,We read with great interest the article by Wang et al which investigated the predictive factors for short-term outcomes related to central subfield foveal thickness (CSFT) after intravitreal bevacizumab (IVB; Avastin, Genentech Inc., South Francisco, CA, USA) injections in 60 patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). The authors concluded that IVB significantly improved visual acuity and CSFT after 3mo.